{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:24:14Z","timestamp":1789943054088,"version":"4.0.1"},"reference-count":69,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2015.0001","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:24:09Z","timestamp":1525238649000},"source":"Crossref","is-referenced-by-count":50,"title":["The Problems of Long-Term Treatment With Benzodiazepines and Related Substances"],"prefix":"10.3238","author":[{"given":"Katrin","family":"Janhsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Roser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2015,1,5]]},"reference":[{"key":"10.3238\/arztebl.2015.0001_ref1","doi-asserted-by":"crossref","unstructured":"M\u00fcller-Oerlinghausen B: Prescription and misuse of benzodiazepines in the Federal Republic of Germany. Pharmacopsychiatry 1986; 19: 8\u201313.","DOI":"10.1055\/s-2007-1017140"},{"key":"10.3238\/arztebl.2015.0001_ref2","unstructured":"Janhsen K: Die stille Sucht: Medikamentenabh\u00e4ngigkeit ist weiblich. In: Glaeske G, Janhsen K (eds.): GEK-Arzneimittel-Report 2007. St. Augustin: Asgard 2007; 125\u201339."},{"key":"10.3238\/arztebl.2015.0001_ref3","doi-asserted-by":"crossref","unstructured":"Holzbach R: Benzodiazepin-Langzeitgebrauch und -abh\u00e4ngigkeit. Fortschr Neurol Psychiatr 2010; 78: 425\u201334.","DOI":"10.1055\/s-0029-1245354"},{"key":"10.3238\/arztebl.2015.0001_ref4","doi-asserted-by":"crossref","unstructured":"Holzbach R, Martens M, Kalke J, Raschke P: Zusammenhang zwischen Verschreibungsverhalten der \u00c4rzte und Medikamentenabh\u00e4ngigkeit ihrer Patienten. Bundesgesundheitsblatt 2010; 53: 319\u201325.","DOI":"10.1007\/s00103-010-1029-8"},{"key":"10.3238\/arztebl.2015.0001_ref5","doi-asserted-by":"crossref","unstructured":"Verthein U, Martens MS, Raschke P, Holzbach R: Langzeitverschreibung von Benzodiazepinen und Non-Benzodiazepinen. Eine prospektive Analyse \u00fcber 12 Monate. Gesundheitswesen 2013; 7: 430\u20137.","DOI":"10.1055\/s-0032-1321756"},{"key":"10.3238\/arztebl.2015.0001_ref6","unstructured":"Lohse MJ, M\u00fcller-Oerlinghausen B: Mittel zur Behandlung von Alkoholfolgekrankheiten. In: Schwabe U, Paffrath D (eds.): Arzneiverordnungs-Report 2013. Berlin, Heidelberg: Springer 2013; 851\u20133."},{"key":"10.3238\/arztebl.2015.0001_ref7","doi-asserted-by":"crossref","unstructured":"Schwabe U: Benzodiazepine. In: Schwabe U, Paffrath D (eds.): Arzneiverordnungs-Report 2013. Berlin, Heidelberg: Springer 2013; 379\u201380.","DOI":"10.1007\/978-3-642-37124-0"},{"key":"10.3238\/arztebl.2015.0001_ref8","doi-asserted-by":"crossref","unstructured":"Lohse MJ, M\u00fcller-Oerlinghausen B: Hypnotika und Sedativa. In: Schwabe U, Paffrath D (eds.): Arzneiverordnungs-Report 2013. Berlin, Heidelberg: Springer 2013; 641\u201355.","DOI":"10.1007\/978-3-642-37124-0_28"},{"key":"10.3238\/arztebl.2015.0001_ref9","doi-asserted-by":"crossref","unstructured":"Hoffmann F, Glaeske G, Scharffetter W: Zunehmender Hypnotikaverbrauch auf Privatrezepten in Deutschland. Sucht 2006; 52: 360\u20136.","DOI":"10.1024\/2006.06.02"},{"key":"10.3238\/arztebl.2015.0001_ref10","doi-asserted-by":"crossref","unstructured":"Hoffmann F, Glaeske G: Benzodiazepinhypnotika, Zolpidem und Zopiclon auf Privatrezept. Verbrauch zwischen 1993 und 2012. Nervenarzt 2014; 85: 1402\u20131409.","DOI":"10.1007\/s00115-014-4016-8"},{"key":"10.3238\/arztebl.2015.0001_ref11","unstructured":"Diemert S, Ganso M, Zagermann-Muncke P: Benzodiazepine und Z-Hypnotika. AMK-Umfrage zum Missbrauch. Pharm Ztg 2013; 158: 20\u20134."},{"key":"10.3238\/arztebl.2015.0001_ref12","doi-asserted-by":"crossref","unstructured":"Hoffmann F, Scharffetter W, Glaeske G: Verbrauch von Zolpidem und Zopiclon auf Privatrezepten zwischen 1993 und 2007. Nervenarzt 2009; 80: 578\u201383.","DOI":"10.1007\/s00115-008-2648-2"},{"key":"10.3238\/arztebl.2015.0001_ref13","unstructured":"Voelker K: Welche Vorgaben gelten f\u00fcr die Verordnung von Benzodiazepinen? Hamb Arztebl 2009; 6: 15."},{"key":"10.3238\/arztebl.2015.0001_ref14","doi-asserted-by":"crossref","unstructured":"Linden M, B\u00e4r T, Helmchen H: Prevalence and appropriateness of psychotropic drug use in old age: results from the Berlin Aging Study (BASE). Int Psychogeriatr 2004; 16: 461\u201380.","DOI":"10.1017\/S1041610204000420"},{"key":"10.3238\/arztebl.2015.0001_ref15","doi-asserted-by":"crossref","unstructured":"Hoffmann F, Pfannkuche M, Glaeske G: Hochverbrauch von Zolpidem und Zopiclon. Querschnittsstudie auf Basis von Krankenkassendaten. Nervenarzt 2008; 79: 67\u201372.","DOI":"10.1007\/s00115-007-2280-6"},{"key":"10.3238\/arztebl.2015.0001_ref16","unstructured":"Kraus L, Pabst A, Gomes de Matos E, Piontek D: Kurzbericht Epidemiologischer Suchtsurvey 2012. Tabellenband: Pr\u00e4valenz der Medikamenteneinnahme und medikamentenbezogener St\u00f6rungen nach Geschlecht und Alter im Jahr 2012. www.ift.de\/fileadmin\/literaturliste\/ESA_2012_Medikamente-Kurzbericht.pdf (last accessed on 23 July 2014)."},{"key":"10.3238\/arztebl.2015.0001_ref17","unstructured":"Knopf H, Melchert HU: Bundes-Gesundheitssurvey: Arzneimittelgebrauch. Konsumverhalten in Deutschland. Benzodiazepin- und\/oder barbiturs\u00e4ure-haltige Psycholeptika. Berlin: Robert-Koch-Institut 2003; 56\u20137."},{"key":"10.3238\/arztebl.2015.0001_ref18","doi-asserted-by":"crossref","unstructured":"Soyka M, Queri S, K\u00fcfner H, R\u00f6sner S: Wo verstecken sich 1,9 Millionen Medikamentenabh\u00e4ngige? Nervenarzt 2005; 76: 72\u20137.","DOI":"10.1007\/s00115-004-1828-y"},{"key":"10.3238\/arztebl.2015.0001_ref19","unstructured":"Mental Health and Drug and Alcohol Office: Drug and alcohol withdrawal clinical practice guidelines \u2013 NSW. www0.health.nsw.gov.au\/poli cies\/gl\/2008\/pdf\/gl2008_011.pdf (last accessed 24 July 2014)."},{"key":"10.3238\/arztebl.2015.0001_ref20","unstructured":"Poser W, B\u00f6ning J, Holzbach R, Schmidt L G: Medikamentenabh\u00e4ngigkeit (Sedativa, Hypnotika, Analgetika, Psychostimulanzien). In: Schmidt L G, Gastpar M, Falkai P, Gabel W (eds): Evidenzbasierte Suchtmedizin. K\u00f6ln: Deutscher \u00c4rzteverlag 2006; 271\u2013307."},{"key":"10.3238\/arztebl.2015.0001_ref21","unstructured":"Frei M, Berends L, Kenny P, et. al.: Alcohol and other drug withdrawal: practice guidelines. 2nd ed. Fitzroy,Victoria: Turning Point Alcohol and Drug Centre 2012."},{"key":"10.3238\/arztebl.2015.0001_ref22","doi-asserted-by":"crossref","unstructured":"Denis C, Fatseas M, Lavie E, Auriacombe M: Pharmacological interventions for benzodiazepine mono-dependance management in outpatient settings. Cochrane Database of Syst Rev 2006; 3: CD005194.","DOI":"10.1002\/14651858.CD005194.pub2"},{"key":"10.3238\/arztebl.2015.0001_ref23","unstructured":"Bundes\u00e4rztekammer in Zusammenarbeit mit der Arzneimittelkommission der deutschen \u00c4rzteschaft: Medikamente \u2013 sch\u00e4dlicher Gebrauch und Abh\u00e4ngigkeit. Leitfaden f\u00fcr die \u00e4rztliche Praxis 2007. K\u00f6ln: Deutscher \u00c4rzteverlag 2007."},{"key":"10.3238\/arztebl.2015.0001_ref24","doi-asserted-by":"crossref","unstructured":"Holzbach R: Der Benzodiazepinentzug und dessen Behandlung. Suchttherapie 2006; 7: 97\u2013106.","DOI":"10.1055\/s-2006-927015"},{"key":"10.3238\/arztebl.2015.0001_ref25","doi-asserted-by":"crossref","unstructured":"Rubio G, Bobes J, Cervera G, Teran A, Perez M, Lopez-Gomez V, Rejas J: Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use. Eur addict res 2011; 17: 262\u201370.","DOI":"10.1159\/000324850"},{"key":"10.3238\/arztebl.2015.0001_ref26","doi-asserted-by":"crossref","unstructured":"Quaglio G, Pattaro C, Gerra G, et al.: High dose benzodiazepine dependence: description of 29 patients treated with flumazenil infusion and stabilized with clonazepam. Psychiatry res 2012; 198: 457\u201362.","DOI":"10.1016\/j.psychres.2012.02.008"},{"key":"10.3238\/arztebl.2015.0001_ref27","doi-asserted-by":"crossref","unstructured":"Saxon L, Borg S, Hiltunen AJ: Reduction of aggression during benzodiazepine withdrawal: effects of flumazenil. Pharmacol biochem behav 2010, 96: 148\u201351.","DOI":"10.1016\/j.pbb.2010.04.023"},{"key":"10.3238\/arztebl.2015.0001_ref28","doi-asserted-by":"crossref","unstructured":"Vicens C, Socias I, Mateu C, et al.: Comparative efficacy of two primary care interventions to assist withdrawal from long term benzodiazepine use: a protocol for a clustered, randomized trial. BMC fam pract 2011; 12: 23.","DOI":"10.1186\/1471-2296-12-23"},{"key":"10.3238\/arztebl.2015.0001_ref29","doi-asserted-by":"crossref","unstructured":"Hajak G, M\u00fcller WE, Wittchen HU, Pittrow D, Kirch W: Abuse and dependence potential for the non-benzodiazepinde hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003; 98: 1371\u20138.","DOI":"10.1046\/j.1360-0443.2003.00491.x"},{"key":"10.3238\/arztebl.2015.0001_ref30","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN): S2-Leitlinie: Therapeutische Ma\u00dfnahmen bei aggressivem Verhalten in der Psychiatrie und Psychotherapie. S2 Praxisleitlinien in Psychiatrie und Psychotherapie 2010; 2."},{"key":"10.3238\/arztebl.2015.0001_ref31","doi-asserted-by":"crossref","unstructured":"H offmann F, Schmiemann G, Windt R: Privat statt Kasse? Einstellungen von Haus\u00e4rzten und Apothekern zur Verordnung von Hypnotika. Dtsch Med Wochenschr 2014, 139: 1153\u20138.","DOI":"10.1055\/s-0034-1369995"},{"key":"10.3238\/arztebl.2015.0001_ref32","unstructured":"Binder W, Kornhuber HH, Waiblinger G: Benzodiazepin-Sucht, unsere iatrogene Seuche \u2013 157 F\u00e4lle von Benzodiazepin-Abh\u00e4ngigkeit. \u00d6ffentliches Gesundheitswesen 1984; 46: 80\u20136."},{"key":"10.3238\/arztebl.2015.0001_ref33","doi-asserted-by":"crossref","unstructured":"Manchikanti L, Malla Y, Wargo BW: Comparative Evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC\/MS\/MS) of urine drug testing. Pain Physician 2011; 14: 259\u201370.","DOI":"10.36076\/ppj.2011\/14\/259"},{"key":"10.3238\/arztebl.2015.0001_ref34","doi-asserted-by":"crossref","unstructured":"Martinez-Cano H, Vela-Bueno A, De Inceta M, Pomalima R, Martinez-Gras I, Sobrino MP: Benzodiazepine types in high versus therapeutic dose dependence. Addiction 1996; 91: 1179\u201386.","DOI":"10.1046\/j.1360-0443.1996.91811799.x"},{"key":"10.3238\/arztebl.2015.0001_ref35","doi-asserted-by":"crossref","unstructured":"Rappa LR, Larose-Pierre M, Payne DR, Eraikhuemen NE, Lanes DM, Kearnes ML: Detoxification from high-dose zolpidem using diazepam. Ann Pharmacotherapy 2004; 38: 590\u20134.","DOI":"10.1345\/aph.1D339"},{"key":"10.3238\/arztebl.2015.0001_ref36","doi-asserted-by":"crossref","unstructured":"Hermos JA, Young MM, Lawler EV, Rosenbloom D, Fiore LD: Long-term, high-dose benzodiazepine prescription in veteran patients with PTSD: influence of preexisting alcoholism and drug abuse diagnosis. J Traumatic Stress 2007; 20: 909\u201314.","DOI":"10.1002\/jts.20254"},{"key":"10.3238\/arztebl.2015.0001_ref37","doi-asserted-by":"crossref","unstructured":"Lader M: Iatrogenic sedative dependence and abuse \u2013 have doctors learnt caution? Addiction 1998; 93: 1133\u20135.","DOI":"10.1046\/j.1360-0443.1998.93811331.x"},{"key":"10.3238\/arztebl.2015.0001_ref38","doi-asserted-by":"crossref","unstructured":"Taylor D: Iatrogenic drug dependence \u2013 a problem in intensive care? Intensive Crit Care Nurs 1999; 15: 95\u2013100.","DOI":"10.1016\/S0964-3397(99)80005-6"},{"key":"10.3238\/arztebl.2015.0001_ref39","doi-asserted-by":"crossref","unstructured":"Hoffmann F: Perceptions of German GPs on benefits and risks of benzodiazepines and Z-drugs. Swiss Med Wkly 2013, 143: w13745.","DOI":"10.4414\/smw.2013.13745"},{"key":"10.3238\/arztebl.2015.0001_ref40","unstructured":"\u00c4rztekammer Hamburg, Kassen\u00e4rztliche Vereinigung Hamburg, Apothekerkammer Hamburg: Verordnung von Benzodiazepinen und deren Analoga. Gemeinsame Handlungsempfehlung von \u00c4rztekammer Hamburg, Kassen\u00e4rztlicher Vereinigung Hamburg und Apothekerkammer. Hamburg 2011."},{"key":"10.3238\/arztebl.2015.0001_ref41","unstructured":"Dieser B\u00e4renkram muss aus dem Verkehr. Der Spiegel 1988; 35: 160\u20137."},{"key":"10.3238\/arztebl.2015.0001_ref42","unstructured":"G\u00fcnther J: Tetrazepam. In: Schwabe U, Paffrath D (eds.): Arzneiverordnungs-Report 2013. Berlin, Heidelberg: Springer 2013; 756\u20138."},{"key":"10.3238\/arztebl.2015.0001_ref43","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte: Ruhen der Zulassungen aller Tetrazepam-haltigen Arzneimittel (z. B. Musaril\u00ae Filmtabletten) zum 1. August 2013. www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RHB\/2013\/rhb-tetrazepam.pdf?__blob=publicationFile&v=5 (last accessed on 23 July 2014)."},{"key":"10.3238\/arztebl.2015.0001_ref44","unstructured":"Bundesverband der Pharmazeutischen Industrie (eds.): Rote Liste. Arzneimittelverzeichnis f\u00fcr Deutschland. Aulendorf: Cantor 1984."},{"key":"10.3238\/arztebl.2015.0001_ref45","unstructured":"Fachinformation Distraneurin\u00ae, Stand: 2\/2011."},{"key":"10.3238\/arztebl.2015.0001_ref46","doi-asserted-by":"crossref","unstructured":"Kraus L, Piontek D, Pabst A, Gomes de Matos E: Studiendesign und Methodik des Epidemiologischen Suchtsurveys 2012. Sucht 2013; 59: 309\u201320.","DOI":"10.1024\/0939-5911.a000274"},{"key":"10.3238\/arztebl.2015.0001_ref47","unstructured":"Glaeske G: Psychotrope und andere Arzneimittel mit Missbrauchs- und Abh\u00e4ngigkeitspotenzial. In: Deutsche Hauptstelle f\u00fcr Suchtfragen e.V. (eds.): Jahrbuch Sucht 2006. Geesthacht: Neuland Verlagsgesellschaft 2006; 87\u2013103."},{"key":"10.3238\/arztebl.2015.0001_ref48","unstructured":"Statistisches Bundesamt: Vorl\u00e4ufige Ergebnisse der Bev\u00f6lkerungsfortschreibung 2011 auf Grundlage des Zensus 2011. Zensusdaten mit dem Stand vom 10. April 2014. www.destatis.de\/DE\/ZahlenFakten\/GesellschaftStaat\/Bevoelkerung\/Bevoelkerungsstand\/Bevoelkerungsstand.html (last accessed 24 July 2014)."},{"key":"10.3238\/arztebl.2015.0001_ref49","unstructured":"NHS West Essex: Guidelines for prescribing and withdrawing benzodiazepines and Z-drugs. A recource for general practitioners. October 2012. (last accessed 24 July 2014)."},{"key":"10.3238\/arztebl.2015.0001_ref50","doi-asserted-by":"crossref","unstructured":"Denis C, Fatseas M, Lavie E, Auriacombe M: Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database of Syst Rev 2013, 6: CD005194. doi: 10.1002\/14651558.CD005194.pub3.","DOI":"10.1002\/14651858.CD005194.pub3"},{"key":"10.3238\/arztebl.2015.0001_ref51","unstructured":"Holzbach R: Jahrelange Einnahme von Benzodiazepinen. Wann ein Entzug notwendig ist und wie er gelingt. MMW Fortschr Med 2009; 151: 36\u20139."},{"key":"10.3238\/arztebl.2015.0001_ref52","doi-asserted-by":"crossref","unstructured":"Oulis P, Konstantakopoulos G: Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependance. Expert opin investig drugs 2012, 21: 1019\u201329.","DOI":"10.1517\/13543784.2012.685651"},{"key":"10.3238\/arztebl.2015.0001_ref53","doi-asserted-by":"crossref","unstructured":"Bobes J, Rubio G, Teran A, et al.: Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice. Eur psychiatry 2012; 27: 301\u20137.","DOI":"10.1016\/j.eurpsy.2010.12.004"},{"key":"10.3238\/arztebl.2015.0001_ref54","doi-asserted-by":"crossref","unstructured":"Gerra G, Zaimovic A, Giusti F, Moi, G, Brewer C: Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized placebo-controlled study. Addict Biol 2002; 7: 385\u201395.","DOI":"10.1080\/1355621021000005973"},{"key":"10.3238\/arztebl.2015.0001_ref55","doi-asserted-by":"crossref","unstructured":"Parr JM, Kavanagh DJ, Young RM, Mitchell G: Acceptability of cognitive-behaviour therapy via the Internet for cessation of benzodiazepine use. Drug alcohol rev 2011; 30: 306\u201314.","DOI":"10.1111\/j.1465-3362.2010.00183.x"},{"key":"10.3238\/arztebl.2015.0001_ref56","doi-asserted-by":"crossref","unstructured":"Ashton H: The diagnosis ang management of benzodiazepine dependence. Curr Opinion Psychiatry 2005; 18: 249\u201355.","DOI":"10.1097\/01.yco.0000165594.60434.84"},{"key":"10.3238\/arztebl.2015.0001_ref57","doi-asserted-by":"crossref","unstructured":"Oude Voshaar RC, Couv\u00e9e JE, Balkom A van, Mulder P, Zitman FG: Strategies for discontinuing long-term benzodiazepine use. Br J Psychiatry 2006; 189: 213\u201320.","DOI":"10.1192\/bjp.189.3.213"},{"key":"10.3238\/arztebl.2015.0001_ref58","doi-asserted-by":"crossref","unstructured":"Tyrer P, Ferguason B, Hallstr\u00f6m C, et al.: A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. Br J Psychiatry 1996; 168: 457\u201361.","DOI":"10.1192\/bjp.168.4.457"},{"key":"10.3238\/arztebl.2015.0001_ref59","unstructured":"Lugoboni F, Quaglio G: Exploring the dark side of the moon: the treatment of benzodiazepine tolerance. Br J Clin Pharmacology 2013; 1\u20133."},{"key":"10.3238\/arztebl.2015.0001_ref60","doi-asserted-by":"crossref","unstructured":"Oude Voshaar RC, Gorgels WJ, Mol AJ, et al.: Predictors of long-term benzodiazepine abstinence in participants of a randomized controlled benzodiazepine withdrawal program. Can J Psychiatry 2006, 51: 445\u201352.","DOI":"10.1177\/070674370605100706"},{"key":"10.3238\/arztebl.2015.0001_ref61","doi-asserted-by":"crossref","unstructured":"Lader M: History of Benzodiazepine Dependance. J Subst Abuse Treat 1991; 8: 53\u20139.","DOI":"10.1016\/0740-5472(91)90027-8"},{"key":"10.3238\/arztebl.2015.0001_ref62","unstructured":"Deutsche Gesellschaft f\u00fcr Neurologie (DGN): S1-Leitlinie: Status epilepticus im Erwachsenenalter. 2012. (last accessed 2 December 2014)."},{"key":"10.3238\/arztebl.2015.0001_ref63","unstructured":"Weltgesundheitsorganisation: WHO Model List of Essential Medicines. 18 th list. April 2013. (last accessed 24 July 2014)."},{"key":"10.3238\/arztebl.2015.0001_ref64","unstructured":"Mavrogiorgou P, Br\u00fcne M, Juckel G: The management of psychiatric emergencies. Dtsch Arztebl Int; 108: 222\u201330."},{"key":"10.3238\/arztebl.2015.0001_ref65","doi-asserted-by":"crossref","unstructured":"Mickel C: 3 things to consider before relying solely on point of care tests for determining benzodiazepine use in chronic pain. Pain Physician 2012; 15: E151\u20138.","DOI":"10.36076\/ppj.2012\/15\/E154"},{"key":"10.3238\/arztebl.2015.0001_ref66","unstructured":"National Institute for Clinical Excellence: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. www.nice.org.uk\/guidance\/ta77 (last accessed 2 December 2014)."},{"key":"10.3238\/arztebl.2015.0001_ref67","doi-asserted-by":"crossref","unstructured":"Johansson BA, Berglubnd M, Hanson M, P\u00f6hlen C, Persson I: Dependence on legal drugs among alcoholics. Alcohol Alcohol 2003; 38: 613\u20138.","DOI":"10.1093\/alcalc\/agg123"},{"key":"10.3238\/arztebl.2015.0001_ref68","unstructured":"Faust B: Doctors and detailers: the benzodiazepine scandal. Austr Nurses J 1991; 20: 12\u20133."},{"key":"10.3238\/arztebl.2015.0001_ref69","doi-asserted-by":"crossref","unstructured":"Lader M: Benzodiazepines revisited-will we ever learn? Addiction 2011; 106: 2086\u2013109.","DOI":"10.1111\/j.1360-0443.2011.03563.x"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T08:11:50Z","timestamp":1638778310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,5]]},"references-count":69,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2015.0001","relation":{"is-cited-by":[{"id-type":"doi","id":"10.1080\/10826084.2017.1355386","asserted-by":"object"}]},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,5]]}}}